Literature DB >> 9830062

Fusions between Epstein-Barr viral nuclear antigen-1 of Epstein-Barr virus and the large T-antigen of simian virus 40 replicate their cognate origins.

A Aiyar1, B Sugden.   

Abstract

Epstein-Barr viral nuclear antigen-1 (EBNA-1) is required for the stable replication of plasmids that contain oriP, the origin of DNA synthesis used during the latent phase of the Epstein-Barr virus life cycle. EBNA-1 acts post-synthetically through unknown mechanisms to facilitate the continued synthesis of oriP plasmids in ensuing S phases. In contrast to viral replicons such as that of SV40, DNA synthesis of oriP is restricted to a single round during each cell cycle. Large T-antigen of SV40 is a DNA helicase and activates the synthesis of SV40 DNA by recruiting cellular proteins required for DNA synthesis to the origin of SV40. Using fusion proteins of EBNA-1 and large T-antigen, we tested whether tethering large T-antigen to oriP is sufficient to initiate multiple rounds of DNA synthesis from oriP during each cell cycle. We report here that, although these fusion proteins retain the biological activities of both EBNA-1 and large T-antigen, their constituent proteins do not confer the properties of one on the other. Thus, it is not possible to subvert the cellular controls that restrict DNA synthesis from oriP to a single round per cell cycle. These results also provide insights into architectural constraints at oriP and at the SV40 ori.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9830062     DOI: 10.1074/jbc.273.49.33073

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  The linking regions of EBNA1 are essential for its support of replication and transcription.

Authors:  D Mackey; B Sugden
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

2.  The cis-acting family of repeats can inhibit as well as stimulate establishment of an oriP replicon.

Authors:  E R Leight; B Sugden; E R Light
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Establishment of an oriP replicon is dependent upon an infrequent, epigenetic event.

Authors:  E R Leight; B Sugden
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

4.  The amino terminus of Epstein-Barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes.

Authors:  John Sears; Maki Ujihara; Samantha Wong; Christopher Ott; Jaap Middeldorp; Ashok Aiyar
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  Essential elements of a licensed, mammalian plasmid origin of DNA synthesis.

Authors:  Jindong Wang; Scott E Lindner; Elizabeth R Leight; Bill Sugden
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

6.  Optimal transactivation by Epstein-Barr nuclear antigen 1 requires the UR1 and ATH1 domains.

Authors:  Gyanendra Singh; Siddhesh Aras; Arnold H Zea; Shahriar Koochekpour; Ashok Aiyar
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

7.  The beta-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression.

Authors:  Vânia Gonçalves; Paulo Matos; Peter Jordan
Journal:  RNA       Date:  2008-10-24       Impact factor: 4.942

8.  The spacing between adjacent binding sites in the family of repeats affects the functions of Epstein-Barr nuclear antigen 1 in transcription activation and stable plasmid maintenance.

Authors:  Christy Hebner; Julie Lasanen; Scott Battle; Ashok Aiyar
Journal:  Virology       Date:  2003-07-05       Impact factor: 3.616

9.  Diametrically opposed effects of hypoxia and oxidative stress on two viral transactivators.

Authors:  Amber T Washington; Gyanendra Singh; Ashok Aiyar
Journal:  Virol J       Date:  2010-05-10       Impact factor: 4.099

10.  Zinc coordination is required for and regulates transcription activation by Epstein-Barr nuclear antigen 1.

Authors:  Siddhesh Aras; Gyanendra Singh; Kenneth Johnston; Timothy Foster; Ashok Aiyar
Journal:  PLoS Pathog       Date:  2009-06-12       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.